Hantz Financial Services’s Tonix Pharmaceuticals TNXP Stock Holding History

Hantz Financial Services’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4	Closed	-$51K	–	1173
2023 Q1	$51K	Buy	4 +1	+33%	+$17.2K	﹤0.01%	622
2022 Q4	$24K	Buy	3 +2	+200%	+$17.3K	﹤0.01%	663
2022 Q3	$9K	Hold	1	–	–	﹤0.01%	760
2022 Q2	$17K	Buy	+1	New	+$73.8K	﹤0.01%	677
2022 Q1	–	Hold	0	–	–	–	758

Other funds holding TNXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Hantz Financial Services's TNXP Position: Q2 2023 in Review

Hantz Financial Services sold out of Tonix Pharmaceuticals (TNXP) in Q2 2023, closing a stake of 4 shares — an estimated $51K sold.

Hantz Financial Services first reported a position in TNXP in Q2 2022 and held it in 4 quarters. The position peaked at $51K in Q1 2023. 14 funds tracked by Wall St. Rank hold TNXP as of Q2 2023.

Hantz Financial Services reported no remaining Tonix Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Hantz Financial Services sold 4 Tonix Pharmaceuticals shares in Q2 2023, an estimated $51K.
Hantz Financial Services first reported a position in Tonix Pharmaceuticals in Q2 2022 and held it in 4 quarters.
Hantz Financial Services's Tonix Pharmaceuticals position peaked at $51K in Q1 2023.
14 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2023.

Based on Hantz Financial Services's 13F filing for Q2 2023, filed 14 Aug 2023.